Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aspect Medical Systems

This article was originally published in The Gray Sheet

Executive Summary

Negotiates venture financing of approximately $8.3 mil. Harvard Management Company's Aeneas Group will provide funds, as will current investors Merrill Pickard Anderson & Eyre, New Enterprise Associates, Catalyst Ventures, Mayfield Fund and Sutter Hill Ventures. Upon completion of the transaction, Aeneas Vice President Marc Silver will become the seventh member of Framingham, Massachusetts-based Aspect's board. Proceeds will be used for sales expansion, for marketing and manufacturing operations and to "accelerate certain research and development efforts," according to the firm. Aspect began shipments of its first product, the A-1000 electroencephalographic (EEG) monitor, this month. The firm also is conducting trials to support a PMA application for an anesthesia monitoring system.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000703

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel